José Luis Alonso-Romero

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy

Caridad Marín Hernández, Pedro José Gil Vázquez, P.J. Galindo Fernández et al. · Clinical & Translational Oncology · 2017 · 109 citations

Medicine, Immunology, Oncology +16

Immunohistochemical Findings in Acute Atherosis Associated With Intrauterine Growth Retardation

Caelos Labarrere, José Luis Alonso-Romero, Jorge A. Manni et al. · American Journal Of Reproductive Immunology · 1985 · 52 citations

Life Sciences, Immunology, Pathology +17

Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

José Manuel Pérez-García, Antonio Llombart‐Cussac, María Gión et al. · European Journal of Cancer · 2021 · 41 citations

Medicine, Oncology, Pharmacology +16

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

Sara A. Hurvitz, Aditya Bardia, Vanesa Quiroga et al. · The Lancet Oncology · 2023 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17